THE NECESSITY OF ADVANCED RAS-MUTATIONS INVESTIGATION FOR COLORECTAL CANCER TREATMENT
https://doi.org/10.17650/2220-3478-2014-0-1-9-15
Abstract
Retrospective analysis of 3 randomized clinical trials of WT-KRAS metastatic colorectal cancer patients (PRIME, PEAK, FIRE-3) is presented. The PRIME study demonstrated increase in median overall survival (OS) in group receiving panitumumab in addition to FOLFOX4 chemotherapy – 26.0 vs 20.2 months (р = 0.04). The РЕАК trial compared FOLFOX4 + panitumumab and FOLFOX4 + bevacizumab in the same patient group in first-line treatment, a significant increase in median PFS (13.1 vs 9.5 months, p = 0.03) and non-significant increase in median OS (41.3 vs 28.9 months, p = 0.058) was achieved. The FIRE trial demonstrated FOLFIRI + cetuximab superiority when compared to FOLFIRI + bevacizumab in median OS 33.1 vs 25.6 months (р = 0.011). All trials retrospectively analyzed additional RAS mutations, allowing to select a subgroup of patients, who benefit most from EGFR inhibition.
About the Author
V. A. Gorbunova
Department of chemotherapy, N. N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Siegel R., Naishadham M. A., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10–29.
2. Злокачественные новообразования в России в 2012 году (заболеваемость и смертность). Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М.: ФГБУ «МНИОИ им. П. А. Герцена» Минздрава России, 2014.
3. Saltz L. B., Cox J. V., Blanke C. et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343(13):905–14.
4. Van Cutsem E., Tabernero J., Lakomy R. Intravenous aflibercept versus placebo in combination with irinotecan / 5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC 10262 – VELOUR). Ann Oncol 2011;22(Suppl 5):v10 – v18.
5. Hurwitz H., Fehrenbacher L., Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 Jun 3;350(23):2335–42.
6. Giantonio B. J., Catalano P. J., Meropol N. J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007 Apr 20;25(12):1539–44.
7. Arnold D., Andre T., Bennouna J. et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). J Clin Oncol 2012;30 (suppl; abstr CRA3503).
8. Douillard J. Y., Oliner K. S., Siena S. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013 Sep;12;369(11):1023–34.
9. Karthaus M., Schwartzberg L. Updated overall survival (OS) analysis of novel predictive KRAS / NRAS mutations beyond KRAS exon 2 in PEAK: A 1st-line phase 2 study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC). ESMO 2013, abst. 2262.
10. Heinemann V. Late breaking abstract: Analysis of KRAS / NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. ESMO 2013, abst. 17.
Review
Views:
545
Email this article 